11β-hydroxylase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
|||
| Line 11: | Line 11: | ||
* Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns.<ref name="pmid1554023">{{cite journal| author=Rösler A, Leiberman E, Cohen T| title=High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. | journal=Am J Med Genet | year= 1992 | volume= 42 | issue= 6 | pages= 827-34 | pmid=1554023 | doi=10.1002/ajmg.1320420617 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1554023 }} </ref> | * Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns.<ref name="pmid1554023">{{cite journal| author=Rösler A, Leiberman E, Cohen T| title=High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. | journal=Am J Med Genet | year= 1992 | volume= 42 | issue= 6 | pages= 827-34 | pmid=1554023 | doi=10.1002/ajmg.1320420617 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1554023 }} </ref> | ||
===Case Fatality Rate=== | ===Case Fatality Rate=== | ||
* The | * The case fatality rate of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is highest. | ||
===Age=== | ===Age=== | ||
* Patients of all age groups may develop congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.<ref> Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Wikipedia (2016). https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_11%CE%B2-hydroxylase_deficiency Accessed on January 29, 2016</ref> | * Patients of all age groups may develop congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.<ref> Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Wikipedia (2016). https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_11%CE%B2-hydroxylase_deficiency Accessed on January 29, 2016</ref> | ||
Revision as of 16:57, 9 February 2016
|
Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics |
|
FDA on 11β-hydroxylase deficiency epidemiology and demographics |
|
CDC on 11β-hydroxylase deficiency epidemiology and demographics |
|
11β-hydroxylase deficiency epidemiology and demographics in the news |
|
Blogs on 11β-hydroxylase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is approximately 1 per 100,000 individuals the United States. Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects males and females equally. Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.
Epidemiology and Demographics
Prevalence
- The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals.
Incidence
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns.[1]
Case Fatality Rate
- The case fatality rate of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is highest.
Age
- Patients of all age groups may develop congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.[2]
Gender
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects males and females equally.
Race
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.
References
- ↑ Rösler A, Leiberman E, Cohen T (1992). "High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco". Am J Med Genet. 42 (6): 827–34. doi:10.1002/ajmg.1320420617. PMID 1554023.
- ↑ Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Wikipedia (2016). https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_11%CE%B2-hydroxylase_deficiency Accessed on January 29, 2016